Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing.
Jordan
V C
VC
D000368:Aged; D001943:Breast Neoplasms / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control*; D004334:Drug Administration Schedule; D015914:Estrogen Replacement Therapy / Q000379:methods / Q000592:standards; D004968:Estrogens, Non-Steroidal / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D008525:Medroxyprogesterone / Q000494:pharmacology; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D045167:Progesterone Congeners / Q000494:pharmacology; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology* / Q000627:therapeutic use; D013629:Tamoxifen / Q000494:pharmacology
D004968:Estrogens, Non-Steroidal; D045167:Progesterone Congeners; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride; D002784:Cholesterol; D008525:Medroxyprogesterone